Penumbra, Inc. (PEN) Earnings Call Transcript & Summary
May 7, 2024
Earnings Call Speaker Segments
Cecilia Furlong
executiveThanks, operator. I'm glad all of you could join us today as we review what Penumbra achieved in the first quarter of 2024. Our press release is available, and with it you'll find the financial tables, which include a reconciliation between GAAP and non-GAAP figures, all posted beneath the Investors section of our website, www.penumbrainc.com. During this call, we intend to offer forward-looking statements in accordance with the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Those statements will address areas such as our financial performance, commercialization efforts, clinical trials, regulatory status, quality, compliance, and business trends. Our actual outcomes could end up substantially different from anything those forward-looking statements claim or suggest, thanks to various risks and uncertainties — including the ones listed in our 10-K covering the year that closed on December 31, 2023, which we filed with the SEC. For that reason, we strongly advise against putting excessive weight on such statements, and we suggest you look over our routine submissions to the SEC, such as the 10-K referenced above, to get a more complete picture of these factors and additional risks capable of impacting either our results down the road or the trading value of our shares. Penumbra accepts no obligation to refresh or amend any forward-looking statements because of fresh data, later occurrences, changes, or any other reason. During this call, we report revenue and gross margin according to GAAP, whereas operating expenses, operating income, and adjusted EBITDA appear on a non-GAAP footing. You can find the matching GAAP figures, along with a bridge from GAAP to non-GAAP financial measures, in the press release we have made available. When we talk about non-GAAP operating expenses and operating income, we're leaving out a couple of things. First, amortization of acquired intangible assets — that came to $2.4 million in Q1 2024 and also $2.4 million in Q1 2023. Second, there's $4.8 million tied to non-recurring litigation-related expenses. That figure covers settlement costs along with legal fees from wage and hour complaints that were filed against the company back in 2023, and it falls in the first quarter of 2024. As for Adjusted EBITDA, it strips out those same non-recurring litigation-related expenses plus stock compensation expense. Up next, Adam Elsesser, who serves as Penumbra's Chairman and CEO, is going to give everyone a business update. After that, Maggie Yuen, our Chief Financial Officer, will walk through the financial results for the first quarter of 2024, and then Jason Mills, our Executive Vice President of Strategy, will go over what we're expecting for 2024 guidance. Having said that, I'd now like to hand things over to Adam Elsesser.
Adam Elsesser
executiveThanks, Cecilia. Good afternoon, everyone, and thanks for being on the call for Penumbra's first quarter 2024 results. For Q1, total revenues came in at $278.7 million, which is up 15.4% versus a year ago as reported, or 15.2% in constant currency terms. U.S. thrombectomy revenue rose 35.2% from the same quarter last year, reaching $150.3 million, powered by ongoing robust market expansion and share gains from Lightning Flash and Lightning Bolt 7. International thrombectomy likewise beat our expectations during Q1, up 10.7% year-over-year despite a tough comparison to last year. All in all, we got off to a solid start this year and are seeing favorable trends across our core markets, our computer-assisted vacuum thrombectomy business in VTE and arterial, and our leading stroke portfolio. That gives us added confidence we can achieve robust growth of 27%-30% in U.S. thrombectomy and 16%-20% overall in 2024. Beyond our dedication to strong revenue growth, we're also concentrating on margin expansion and boosting profitability. We're ahead of plan to deliver 100 to 150 basis points of gross margin expansion in 2024, and we're confident we can lift gross margins above 70% within the next 24 to 30 months; we're also on track to achieve at least 100 to 200 basis points of operating margin expansion this year, including the investments we're making in our U.S. commercial team and market access efforts, both of which should help us sustain strong growth going forward. Operating income for Q1 was $19.3 million, or 6.9% of revenue, up 260 basis points from the same period last year. Looking ahead, we anticipate operating margin expansion will outpace gross margin expansion for the foreseeable future. Despite the strong growth in U.S. thrombectomy over the past few years, clinically significant clot burden remains one of the most undertreated acute issues in healthcare today. We're well positioned to broaden access to CAVT and make treating these patients safer, simpler, and faster — something we firmly believe, and are committed to continually proving, benefits patients, physicians, and hospital systems. Over the past several quarters, we've laid out our strategy to deliver outsized revenue growth in thrombectomy over the near, medium, and long term, through a mix of continued innovation with our CAVT platform, optimizing our commercial team in both the U.S. and international markets, and building robust clinical and health economics evidence for our CAVT products. With this collective work, we're confident we'll keep catalyzing adoption of CAVT and drive utilization toward the majority of the 1.25 million applicable clot patients in the United States each year across the five vascular beds we address today. We fully launched Lightning Flash 2.0 in late April, following outstanding outcomes from the evaluation cases done in early April. Lightning Flash 2.0 is proving in practice what we saw on the bench. This product takes the benefits of CAVT in VTE even further. There's clearly pent-up demand building for Lightning Flash 2.0, and when you combine that with the bigger commercial team we've built up over the last 2 quarters, our thrombectomy business in the U.S. is well positioned to keep driving growth for us in these markets throughout this year and beyond. On top of that, we're making real progress in our innovation pipeline and remain on track to bring out 3 more CAVT products over the coming 12 months, with at least 1 of them expected before the end of 2024. All in all, we remain dedicated to ongoing innovation that expands what CAVT can do and how far it can reach, head to toe. Beyond VTE and arterial, the next vascular bed we'll tackle with CAVT is stroke. Things are going extremely well with enrollment in our THUNDER study, and the outcomes and physician engagement have us very encouraged. At this point we hold close to 60% market share in the U.S. stroke market and anticipate picking up additional share through 2024, prior to a Thunderbolt launch, which will take our leadership position even further. We're also feeling more energy and involvement from large healthcare systems that want to partner with us as the industry leader on expanding interventional stroke care to far more patients across their networks. With our proprietary stroke technology portfolio, our standing in the field, and our scale, we have a unique capability to carry out this work alongside healthcare systems going forward. I'll hand the call over to Maggie now to walk through our financial results for the first quarter of 2024.
Maggie Yuen
executiveThank you, Adam. Hello, everyone, and good afternoon. I'll take you through the financial results we posted for Q1 2024. A quick note before I begin — the revenue and gross margin numbers I cite today are GAAP figures, while operating expenses, operating income, and adjusted EBITDA are all non-GAAP. In the press release we issued, you'll find both the matching GAAP measures and a reconciliation of GAAP to non-GAAP financial measures. Total revenues for the quarter that closed on March 31, 2024 were $278.7 million, up 15.4% as reported and up 15.2% in constant currency compared with the first quarter of 2023. In terms of where those sales came from geographically in Q1 2024, 75.2% were generated in the U.S., while 24.8% came from markets outside the country. U.S. growth was 22%, driven by a 35.2% jump in our thrombectomy franchise. International regions slipped 0.7%, which reflects weaker revenue overall in our embolization and access products, partially offset by greater thrombectomy volume in Europe, APAC, Canada, and Latin America. Let's turn now to revenue by product. During the first quarter of 2024, our global thrombectomy business generated $187.7 million, an increase of 29.5% as reported and 29.3% in constant currency compared with the same period a year earlier. Growth of 35.2% in the U.S. and 10.7% internationally versus last year's comparable period shows the strong momentum our CAVT products carry. Our embolization and access business posted $91 million in the first quarter of 2024, a decline of 5.7% as reported and 6% in constant currency, largely due to an overall drop in international markets. Moving on to gross margin. For the first quarter of 2024, gross margin reached 65%, compared with 62.6% in the first quarter of 2023. That works out to a 240 basis point gain, attributable to a favorable thrombectomy product mix in each region as well as solid productivity, partially offset by increased material costs and investment in direct labor capacity related to new product launches and rising demand. We continue to expect 100 to 150 basis points of gross margin expansion in 2024. I'll now go over our non-GAAP operating expenses, non-GAAP operating income and margin, and adjusted EBITDA. Operating expense totaled $161.8 million for the quarter, equal to 58.1% of revenue, compared with $170.7 million, or 58.3% of revenue, in last year's same quarter. Research and development expenses in Q1 2024 were $24.6 million, versus $20 million in Q1 2023. SG&A expenses in Q1 2024 totaled $137.2 million, or 49.2% of revenue, compared with $120.7 million, or 50% of revenue, in Q1 2023. With the first quarter carrying higher seasonal expenditures, we expect ongoing leverage in our SG&A spending as a percentage of revenue. In the first quarter of 2024, we recorded operating income of $19.3 million, or 6.9% of revenue, compared with operating income of $10.4 million, or 4.3% of revenue, in the same period a year ago. We anticipate continuing to drive gains in operating margin between 100 and 200 basis points across 2024. Adjusted EBITDA reached $37.6 million for us, equal to 13.5% of overall revenue, compared with 11.4% during the same period a year earlier. Turning to cash flow and the balance sheet, we ended the first quarter holding $313.5 million across cash, cash equivalents, and marketable securities, while carrying zero debt. That represents a rise of $24.3 million, driven by operating profitability along with improved working capital terms. We expect these favorable operating cash flow trends to persist through 2024. With that, I'll pass things over to Jason, who will take you through the guidance. On a comparable basis, the figures came in at $140.7 million and $144.4 million.
Jason Mills
executiveThanks, Maggie, and good afternoon, everyone. We saw robust momentum in our U.S. thrombectomy business during Q1, the U.S. rollout of Lightning Flash 2.0 that happened recently, plus ongoing gains in productivity from the larger U.S. commercial organization we've built, all of which support what we're expecting: U.S. thrombectomy growth of 27%-30% and total revenue growth of 16%-20% for the whole of 2024. Just like the cadence remarks we made during February's earnings call, we're looking for global revenue growth during the first six months to land in the mid-teens range, mostly driven by orders we currently forecast from international distributors and when new products are scheduled to launch; after that, we anticipate growth speeding up to the upper portion of our 16%-20% guidance range or beyond during the back half of the year. Our view remains that U.S. thrombectomy growth will stay consistently robust within our guidance range across the year, and we now anticipate that our international thrombectomy franchise will grow somewhat more than what we described on the previous earnings call. Mid- to high-single-digit range for the entirety of 2024, versus the flat to modest growth we mentioned last call; when it comes to embolization and access for the whole year, we're expecting mid-single-digit growth inside the U.S; and no change internationally. With that said, we anticipate that year-over-year growth rates for the U.S; as well as international embolization and access operations will pick up as the year progresses, reaching the low-teens range by Q4, thanks to new product introductions and rising productivity from the bigger commercial team. Finally, we still anticipate solid expansion in gross margin as well as operating margin during 2024. We reaffirm our guidance calling for 100 to 150 basis points of gross margin expansion and 100 to 200 basis points of operating margin expansion every quarter on a year-over-year basis, and for the full year too. Operator, please go ahead and open the call for questions.
Margaret Kaczor
analystHi there, good afternoon, everyone. I appreciate you taking my question. So, first off, I was hoping to ask about a few of the remarks regarding sales team optimization, in both the U.S. and OUS. Clearly, thrombectomy growth in both of those markets appears to be accelerating quite well, and honestly perhaps a bit more robust than what we saw. So, how much of that is due to, you know, how much of that relates to, you know, the current market's expansion and some of the carryover from what you witnessed last year? And in particular, you know, which metrics are you tracking when it comes to those investments? Is it specific geographies? Is it particular market access? You know, where are you concentrating?
Adam Elsesser
executiveThat's a terrific set of questions, Margaret. Allow me to unpack it and remind everybody, from a philosophical standpoint, we usually bring people on after our growth, you know, rather than before our growth, and I believe that's been well understood. And so we were examining last year with- enormous demand for the new CAVT platform, and we simply lacked sufficient staff. We added them late in the year, got them trained and running, brought on additional ones during the first quarter. So the upside this quarter wasn't truly the result of many of those new hires. They're now set going forward for the second, third, and fourth quarter. And so what's actually fueling the growth in the first quarter is really just the effort we set out throughout all of last year concerning both Lightning Flash and Lightning Bolt. And how effective they are, and how many individuals are encountering them and testing them and sticking with it. Naturally, you know, we mentioned April being the quarter when we began doing Flash 2.0 cases, so that isn't included in the first quarter figure; that's still ahead, clearly.
Margaret Kaczor
analystAll right; and, as you're aware, when it comes to guidance, clearly another strong quarter. I want to dig into that a bit further, particularly regarding U.S. thrombectomy. You're sitting at the top of the range, and obviously the first quarter had an easier comp; I understand that angle. That said, you've got these commercial investments you're putting in place that ought to scale up. Also, we're going to get some data that might support the whole market expanding somewhat as the year moves forward. So why shouldn't we keep looking for that, or perhaps even a slight acceleration? Thanks.
Adam Elsesser
executiveYes, Margaret, that's an excellent question. Our present guidance clearly already accounts for quicker growth later in the year. We've factored that in, and the solid beginning to this quarter strengthens how confident we feel about our business. Our guidance, especially the U.S. thrombectomy guidance covering the entire year, captures both that strength and the momentum coming from our products and our commercial team. I believe we're positioned quite well as we consider how the year plays out.
Margaret Kaczor
analystOkay. Thanks.
Adam Elsesser
executiveThank you.
Joanne Wuensch
analystEvening, and thanks for fielding my question. Actually, there are two things I'd like to ask. It appears OUS sales are getting better, or at least are anticipated to get better over the course of the year. Could you kind of walk us through the reasons behind that? Then my next question relates to margins. From what I hear, your attention has shifted somewhat more toward growth as well as operating margins. Would you mind laying out, not only growth margins, but across the entire income statement, which levers are available for you to pull in order to reach that? Thanks.
Jason Mills
executiveYes. Margaret — sorry, Joanne — this is Jason. I'll handle the first one, and then Maggie and Adam can address the second one, if that works. Internationally, the cadence usually does ramp up as the year progresses. Also, in Europe, to use that as an illustration, our newest RED stroke products are only now launching there; so you can picture how we expect that cadence to improve, and then during the back half of the year, we believe in Europe they will receive the new CAVT portfolio; on top of that, worldwide, the timing of international orders, as we've discussed, is something we have fairly good visibility into. That's the reason the guidance, the comprehensive guidance, essentially captures that cadence for total revenue across the year. Maggie?
Maggie Yuen
executiveYeah, and regarding where we're concentrating on operating margin — I mean, besides the better product mix you're seeing flow through to gross margin on the operating side, I mean, much of the SG&A infrastructure spending we undertook over the past 2 years is going to keep delivering scalability and, honestly, that applies throughout every part of SG&A.
Joanne Wuensch
analystExcellent. Thank you.
Jason Mills
executiveThank you.
Adam Elsesser
executiveThanks.
Bill Plovanic
analystExcellent. I appreciate you fielding my question. Good evening. Regarding the thrombectomy market in the U.S., we clearly receive many inquiries about it, and it's a major catalyst for you. I was hoping you might assist in breaking down what portion of that expansion comes from VTE as opposed to arterial, and then what share of it stems from ASP rather than being purely volume-related? Since, as you know, from what I gather, you've enjoyed an ASP lift during the past year, and I'm simply attempting to grasp a bit more detail, if that's possible. Thanks. I appreciate it.
Adam Elsesser
executiveYes, I believe that's an excellent question. Allow me to attempt to provide some insight into it. Clearly, our CAVT offerings generated the bulk of that expansion, with FLASH persisting in capturing share and sparking fresh uptake. Additionally, both kept delivering solid results on the arterial front; furthermore, our stroke segment experienced quite robust expansion, more or less inside the guidance range we provided, since stroke keeps registering meaningful advances, and we anticipate that will persist. If I were to, well, consider it, during the prior year, there was a certain combination of pricing and volume, clearly, but at this point we're lapping that. As you know, that occurred; we introduced FLASH at the close of the start of 2023; therefore, nearly all of this constitutes fresh business, and pricing isn't truly mirrored in the growth figure; it's genuinely business, both as the market keeps expanding and we spark uptake, and naturally, a bit of share capture.
Bill Plovanic
analystGreat. And if I could just ask about that litigation cost of $4.8 million that you excluded. I'm just sort of wondering what it consisted of. Is it a one-time item, or will it show up for a few more quarters? I'm not sure whether it's continuing litigation. Just any assistance so we can grasp it.
Adam Elsesser
executiveYeah
Bill Plovanic
analystSo what's the right way for us to frame that? Thanks.
Adam Elsesser
executiveOf course. That's a really good question. As you're aware, everything we make is produced right here in California. Just like every other state, California has its own wage and hour statutes. On top of that, California offers something extra — a private attorney general action — and that can occasionally complicate matters. Our position is firm: we've operated in line with the rules and adhered to them. A few technical violations did occur, and we resolved those claims quite fast; to give you a sense of scale, this is a one-time settlement that puts the whole matter to rest, and now we're free to get back to manufacturing our products and focusing on what's most important.
Bill Plovanic
analystThanks.
Adam Elsesser
executiveThanks, Bill.
Bob Marcus
analystOh, excellent. Thank you for fielding this. Perhaps to kick things off, the thrombectomy growth during the quarter was truly strong. Access and embo came in softer. Could you perhaps walk through the patterns you're observing? What portion is stocking, destocking as opposed to underlying patterns? And also, how should we consider a few of the distinctions among the various products that are progressing.
Adam Elsesser
executiveYes, Robbie, this is Adam. I truly appreciate the question. Clearly, as you're aware, we reported the figures in a different manner so that people could somewhat precisely see what I believe everyone concurs is what's fueling our growth and what holds value within the business. Clearly, you know that within the U.S., we possess market-leading products in both peripheral embo and neuro access, and that business is one we're especially proud of; but we've stated, clearly, that what's fueling our growth will be the thrombectomy. That's where our emphasis will be, going forward. Furthermore, during the Q4 call, we explicitly pointed out that we would be exiting certain markets with our embo and access business in international markets where they weren't financially viable for us as products reimbursements shifted and declined over time. So we essentially indicated that going forward, that's what took place. We also take particular pride in the manner, you know, our thrombectomy business has performed; and keep in mind, in Jason's prepared remarks earlier today, we did state that we'll anticipate seeing growth in our U.S. and embo and access business, you know, as the year advances, and we move, you know, with our new, larger commercial team. On the thrombectomy side, we'll possess the scale and the capacity to concentrate on multiple things as well as some new launches. We just had one with Midway, which is a neuro access tool, at the start of this quarter; so, the business is robust. It simply won't be the thing that fuels the growth in an outsized manner like our thrombectomy business will.
Bob Marcus
analystGreat. Perhaps only one more thing. When we consider U.S. thrombectomy plus O.U.S. thrombectomy at this point, which, as I mentioned, delivered truly strong quarters, how should we view a few of the trends beneath that in neuro compared with peripheral? And can the two be sized in any manner? Many thanks.
Adam Elsesser
executiveDo you mean across the different vascular beds involved in thrombectomy? Well,
Bob Marcus
analystThat's right.
Adam Elsesser
executiveSure, absolutely. If you take a look at what we're seeing in the U.S., clearly the larger expansion was in VTE — that's the venous side, driven by FLASH. With 2.0 now launching, that should keep going as the market expands, as we help drive adoption, and naturally gain share along the way. Things are still going quite well on the arterial side. Stroke performed extremely, extremely well. It came in a bit better than we expected. I believe I addressed a different question a moment ago, noting that our stroke growth landed roughly inside the range we'd provided, which is quite meaningful at this point, given several quarters now where the stroke business has kept on growing. Part of that reflects the market, though a great deal of it is still share, and I think that sets things up nicely as excitement around Thunderbolt keeps building.
Bob Marcus
analystThanks a lot.
Adam Elsesser
executiveThank you.
Larry Biegelsen
analystGood afternoon, and thank you for taking my question. Adam, you're relying on sales of peripheral devices outside the U.S. to fuel next year's growth. Reimbursement abroad has been the sticking point. What evidence can you point to that gives us confidence reimbursement will be settled in time next year to generate that revenue?
Adam Elsesser
executiveYes, I appreciate that question. Let me say this, and I hope it doesn't come across the wrong way: we are not relying on international markets to fuel our growth. I believe I've repeatedly stated that our U.S. thrombectomy business is the thing that will fuel our growth. I think I said as much in the prior question. So that is the thing that will fuel our growth, not only this year, but across many, many years as we keep catalyzing adoption of it. The discussions we're having, the responses we're getting, not only from physicians, but more broadly, are extremely, extremely encouraging. International contributes on top of that, but it is not the centerpiece of our growth going forward. Clearly, it will be somewhat, I won't say slower is the wrong word, but it will be less all at once given what you just mentioned. Particular markets, particular countries will already have reimbursement in place. Some systems draw a distinction between private and public, where we can begin on the private side, but public won't arrive as quickly. All of that is factored in as we look ahead, but I think we have many, many years of growth being fueled by our U.S. thrombectomy business.
Larry Biegelsen
analystAll right, that helps. And for my second question, Adam, regarding THUNDER — those remarks you made about enrollment, plus the encouraging results, if I'm remembering correctly. So what's the newest information on the timeline for finishing enrollment? Does clinicaltrials.gov have it right — it indicates, I believe, primary endpoint completion, when I checked most recently, March 2025. Thanks.
Adam Elsesser
executiveLarry, you're aware, I believe, that I've picked up the lesson about being overly predictive, especially when it comes to this particular trial. So we'll just leave things as clinicaltrials.gov currently shows them. Obviously, we're excited about it — no need to say more. It's moving forward; there's been substantial engagement, plenty of conversation and enthusiasm surrounding it. So for the time being, I think we'll keep the precise timing as it stands.
Larry Biegelsen
analystThank you.
Adam Elsesser
executiveThank you. Appreciate it.
Matthew O'Brien
analystGood afternoon, and thank you for taking my questions. When I look at the after-hours movement in the stock, which is down a bit, my read is that most investors think the guidance for the rest of the year might carry some risk, purely because the comparisons are becoming more difficult. That said, on a two-year stack basis, the thrombectomy business really does look like it's picking up speed. Even EMBO and access in the U.S. appear fairly solid. So when you take into account what you're seeing in terms of new customers, moving deeper into accounts you already have, and then this larger sales force — those people, as you know, don't produce results immediately. It typically takes a while. Considering everything we've discussed, what are the main factors you're relying on for that pickup in the U.S. business across the final three quarters of the year, especially as comparisons become more difficult?
Adam Elsesser
executiveI'm glad you asked that. Let me just establish some context. We've covered guidance far more thoroughly, here and during the Q4 call, where we provided the exact details. Like you're aware, we mentioned that we had substantial visibility into orders from our international distributors and partners regarding when they would place them, and that factor largely explains the variance in those rates, along with the work we can already identify and observe concerning how our U.S. thrombectomy business will expand. There's far greater predictability on our end regarding those rates, and they aren't shifting in any dramatic way over the course of the year. That's something we've now stated on two occasions. So essentially, the shift in the overall company rate boiled down to something we brought up during last quarter's call, and it played out precisely as we had described. And once again, the emphasis remains on what's taking place in the U.S. That ought to serve as our strongest basis for confidence, since everything else for the remainder of the year is fairly locked in based on what our distributor partners have already given us.
Matthew O'Brien
analystAll right. That's helpful. So Adam, you brought up those new offerings headed our way in CAVT, with at least one arriving before this year wraps up. Could that particular item end up being used somewhere in the body that differs from what we typically associate with Penumbra? Or, honestly, whatever broad perspective you can offer regarding what to anticipate from that specific one? Thanks.
Adam Elsesser
executiveWell, once we're nearer, you know, given where the field stands right now, I won't provide further details, since competitors are a factor, but wow, I'm eager to share it. So, kindly hold tight.
Matthew O'Brien
analystUnderstood.
Adam Elsesser
executiveThis is going to be a tremendous amount of fun.
Matthew O'Brien
analystGot it. Thank you.
Adam Elsesser
executiveThank you.
Michael Sarcone
analystHello there, and I appreciate you answering my questions.
Adam Elsesser
executiveCertainly.
Michael Sarcone
analystTo kick things off, could you provide any insight into how you see growth in the U.S. VTE market for the quarter?
Adam Elsesser
executiveHonestly, it has always been quite difficult to tease apart market expansion, meaning new patients, except by examining centers where we've captured 100% of their business and observing that they've expanded; that has held true. We've witnessed ongoing expansion for a number of years at this point. That expansion is still happening. Clearly, especially in VTE, the growth we observed, which was truly impressive this quarter, also reflects some share gains, and that's prior to Flash 2.0; we'll hold off until we wrap up next quarter and observe what impact that has. But I believe it will be a mix, as we mentioned during the prepared remarks, of a meaningful share shift, along with some truly substantial acceleration of adoption or market growth efforts.
Michael Sarcone
analystUnderstood. Thank you, Matt. Now, one more question on that. So, you have discussed market access initiatives quite a bit, and I believe earlier you brought up collaborating with a number of your hospital clients in order to, well, obtain data and cooperate closely with them to clarify the advantages of CAVT across various vascular beds. Could you possibly provide an update on where those initiatives stand?
Adam Elsesser
executiveFor clear reasons, I will not yet get into particular systems and the efforts we are undertaking. My preference is to complete the work first, and then we will observe what comes of it, and after that we can discuss it somewhat more openly; however, I will say this — I am genuinely, genuinely hopeful. Within the hospital community, there is considerable comprehension regarding what I consider to be among the more significant subjects, namely that folks recognize clinically significant clot burden truly ranks as one of the most undertreated acute problems in healthcare; they grasp the impact of leaving it untreated, they grasp the expense of leaving it untreated, and they grasp, more crucially than anything else, the harm to patients from failing to address it. In my view, that is what makes these discussions as constructive as they have been, and allows us to begin the work we are doing; so I am, you know, this quarter, more hopeful. I have personally taken part in another set of those discussions, and I am extremely, extremely hopeful.
Michael Sarcone
analystOkay, thank you.
Adam Elsesser
executiveThank you.
Analyst
analystHi, everyone. I appreciate you taking my question. This is Sam, filling in for Rich. My first one is about U.S. thrombectomy, and I apologize if I overlooked this, but I believe previously you mentioned expecting 27%-30%, within that range, for U.S. thrombectomy this year. Can we still assume that holds from 2Q through 4Q? Just sort of putting in those figures, and I get roughly 29% growth for U.S. thrombectomy this year.
Jason Mills
executiveYeah, thanks for asking. This is Jason. So we mentioned last quarter, and we repeated during this call, that we anticipate U.S. thrombectomy growth falling inside that range. Clearly, in the first quarter, we came in a bit above that range; it was a robust quarter, yet our guidance continues to reflect that range for every quarter over the rest of the year and for the full year. So that's what we're staying with for the time being.
Analyst
analystOkay. My follow-up is similar, but this time it's about margin — in the first quarter, you delivered operating margin growth of slightly over 200 basis points. So I'd like to know which business trends you'd need to observe before you'd feel ready to lift that 100 to 200 basis point guidance for the full year. Thanks.
Maggie Yuen
executiveYes, thank you. Obviously, we're very pleased with how margins performed given the strong start to the year. During Q1, it's normal for us to experience typical increases in material prices as well as some spending tied to productivity for new product launches. Looking at the rest of the year, those gains in productivity are going to keep coming, and our mix of products will keep getting better as well. That gives us solid confidence this expanding margin pattern will carry on.
Jason Mills
executiveYes, and let me build on what was just said. Back in February, when we first shared our guidance for 2024, and we repeated this point again during the current quarter, we noted that because of the pattern of costs we typically experience, we anticipated operating margin growth would land somewhere in that range of 100 to 200 basis points compared with the same period a year earlier for every quarter, which clearly would add up to that kind of increase across the entire year. So grasping the rhythm of how our operating margins move throughout the year really matters.
Adam Elsesser
executiveOkay. Can everyone still hear us?
David Rescott
analystOh, excellent. I appreciate you taking my questions. Adam, I'd like to ask — I caught your comment that Flash 2.0 built on certain strengths of Flash 1.0; so I was hoping you might help us grasp more clearly what has changed within the system; and I also picked up on some remarks regarding pent-up demand that already exists for it. So I'm just wondering what is assumed in that implied Q2 guide compared with the full year, in light of those pent-up demand remarks, and whether, and in what ways, Flash 2.0 might unlock fresh opportunities for the company?
Adam Elsesser
executiveYeah. So let me begin by explaining what we keep seeing and hearing a great deal of, which is that Flash 1.0 clearly performed remarkably well. It cleared a tremendous amount of clot in a very short time. What Flash 2.0 brings is merely an algorithm change, an algorithm update. The catheter itself and its size stayed the same; yet 2.0 clears still more clot, still more quickly, with no need to move to a larger or less suitable catheter size; and I believe the field is getting behind that; they are recognizing the value it delivers. And as you're aware, in this field news travels by word of mouth rather fast. So we're noticing considerable interest, you know, from people who perhaps hadn't been willing to give it a try in PE. They may have used Flash 1.0 in DVT. And that degree of interest is what I was referring to. I think everybody keeps wanting to optimize treatment for these patients. That's what matters. You want to accomplish the three things of greatest importance, and we've made this point before, but those are safety, speed, and simplicity. And Flash 2.0 truly delivers on all of them, and that's the response everyone is experiencing at this moment.
David Rescott
analystAll right, that's excellent. Then perhaps regarding Thunderbolt and the Thunder study. You know, I listened to what was said, and I'm attempting to consider things over a somewhat longer horizon. From what I recall about SENDit, you'd managed to possibly take advantage of some pricing previously, and you talked about that before in terms of securing... assisting in securing additional share. You know, as I consider Thunderbolt, I suppose over a longer timeframe, you know, and the chance that remains ahead, do you still believe there's a possibility to perhaps obtain some form of pricing advantage for a product that carries a premium price when it eventually reaches the market? Thanks.
Adam Elsesser
executiveYes, I believe so. Well, if you look at the broader picture regarding stroke, it isn't vastly different from clots elsewhere in the body, where, you know, product prices have climbed as technology, you know, has advanced and grown more refined. At present, for stroke, physicians employ a variety of methods. They could use aspiration along with a stent retriever; they could do this or that. Consequently, once everything is finished, our cost won't exceed what many others are currently spending; instead, they'll simply be relying entirely on Penumbra's offerings, since those extra ancillary devices become unnecessary when you possess a single straightforward system such as Thunderbolt. And that's precisely what we've already witnessed. That isn't me wishing or speculating; that's what we devoted most of a year to with our CAVT portfolio, in other areas of the body, especially the most, you know, nearest comparison being Lightning Bolt within the arterial system. You know, those technologies are extremely alike, catheters of differing sizes. And we've observed, clearly, a remarkable surge in how much that product gets used. I believe we'll witness a comparable outcome for stroke. I believe we'll begin from a somewhat different position than we did with our earlier technology on the arterial side. Which I believe in the end works in our favor, since we're beginning from a fairly strong leading position against numerous rivals; therefore I think Thunderbolt merely assists us moving ahead.
David Rescott
analystAll right, very helpful. Thank you.
Adam Elsesser
executiveThank you.
Mike Matson
analystYeah, thank you. I just had a single question. Regarding Lightning Flash 2.0, you've built software into the CAVT product. So is this kind of a chance to update the offerings more quickly? To put it differently, should we anticipate seeing 3.0, 4.0, and so on, perhaps within a year or so, while you keep enhancing the software?
Adam Elsesser
executiveYeah, that's an excellent question. Your assumption is correct. Clearly, when it comes to software, quicker cycles are possible compared with hardware, catheters and such. The testing is extremely rigorous, but it's a somewhat different situation. That said, can we keep making this better? Most likely. We're weeks into the launch, and things are going very well. So we haven't yet found flaws that need correcting; I'd say that's a nice problem for us to have, or to enhance. But across the huge amount of work we'll undertake during the next year, I'm certain we'll keep making adjustments and getting better. Of course, the items I mentioned earlier, those three new CAVT products, aren't just another iteration of the same thing; they're newer offerings addressing different areas rather than merely upgrading Lightning Flash to a 3.0. Still, in principle, that could happen.
Mike Matson
analystAll right, understood. And then, Adam, I believe it was you who said something in the prepared remarks about optimizing the commercial team, so I just wanted to ask if you might expand on that. What does that mean, I suppose?
Adam Elsesser
executiveYes. So the way we've always thought about it is that the commercial team shouldn't be the ones driving sales. The products should be desired, and then we need sufficient staff to handle the work and back those products. And we've always had, in my view, the finest commercial team that has ever been put together, and for a great many years we've taken enormous pride in that team. Last year we simply had such a tremendous amount on our plate, you know, with Flash and Bolt both launching simultaneously, our peripheral embolization business, which again is market-leading technology, and with all those new customers we discussed, for a substantial portion of last year. So additional staff were needed to handle the work, and those individuals are now in place. They've joined us. We managed to bring on some of the strongest candidates available. So I believe that right now we truly have a team of the optimal size. As things keep progressing, you know, might we, would we bring on more? Absolutely, that's not out of the question, though it's definitely not something we plan to do in the near term as we move further into this year. I think we've got the team necessary to generate the level of growth we're describing and to serve the patients and physicians we must serve during this year.
Mike Matson
analystOkay, got it. Thank you.
Adam Elsesser
executiveThank you.
Shagun Singh
analystOh, excellent. Many thanks. So, Adam, you're aiming for 16%-20% growth in 2024, compared with your original directional outlook of +20%. I'm curious whether there's a route for you to get back to that +20% growth, and what might drive it? Could it be Flash 2.0? Could it be the new product you hinted at that we might see, you know, this year? And then, you know, the real question is, how should we think about longer-term growth for Penumbra? Is a +20% base case on the horizon? And then, as a quick follow-up on Q2, I'm wondering whether you can give any color. Before today's call, consensus had $302 for sales and $0.61 for EPS. Any, any color would be great. Thanks for taking the questions.
Adam Elsesser
executiveYeah, let me begin with the first part. You know, we've always approached this sort of, you know... Our guidance philosophy is quite simple. We review and factor in everything we know at the moment we provide our guidance, and that's been our method for a while. So I won't sort of stray from that and sort of speculate, you know, what might occur here or there. Clearly, we're very pleased with where the business stands. We sense a great deal of enthusiasm and momentum surrounding the products we've brought into this field, and we're quite proud of that. I think we'll leave the speculation about guidance for a later time beyond what we've stated. That said, and this isn't intended as a remark about guidance, it's intended as a remark about the work ahead of us. I also mentioned in the prepared remarks that 1.25 million people in the U.S. alone have clot in their body, that we should consider doing something about and are potentially now more able to do something about than we've ever been in the past; and obviously, that sets out the work we need to do, and that will obviously affect our future thinking about how the business will grow. But it's too early to do that, and we're gonna concentrate on what we're doing right now.
Jason Mills
executiveYes, and Shagun, regarding what you asked next, we restated earlier today the pattern for how revenue should increase over the rest of this year. On the February call where we first gave guidance, we communicated the identical message: we anticipated the opening portion of the year landing within the mid-teens. As you clearly observed today, we posted growth just past 15%. We also indicated that during the latter six months, we'd be, you know, at the upper boundary or beyond; a piece of that comes from the visibility we possess around the international sequence; and, naturally, we've discussed extensively our thrombectomy operation in the U.S., along with the commercial team and the products, Flash 2.0 being one of them. So I believe, we aimed to be thorough in what I said in my prepared remarks, providing the business components so you can build your models. But I'm glad to address any additional questions if that isn't sufficient.
Shagun Singh
analystThank you.
Adam Elsesser
executiveThank you.
Cecilia Furlong
executiveThanks, operator. Our management team and I want to express our appreciation once more for everyone being here with us today and for the attention you've shown toward Penumbra. We're eager to bring you up to speed during our call covering the second quarter.
Operator
operatorThis concludes today's conference call. You may now disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Penumbra, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Penumbra, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Penumbra, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.